Brief: Frequency Therapeutics Reports Final Results From Four-Arm, Phase 2A Study Of FX-322

Korro Bio

30/06/2021 23:31

June 30 (Reuters) - Frequency Therapeutics Inc  FREQ.O :
    * FREQUENCY THERAPEUTICS - REPORTED FINAL RESULTS FROM
FOUR-ARM,
PHASE 2A STUDY OF FX-322 IN 95 SUBJECTS AGED 18-65, WITH MILD TO
MODERATELY SEVERE ACQUIRED SENSORINEURAL HEARING LOSS
    * FREQUENCY THERAPEUTICS - END-OF-STUDY RESULTS SHOWED 4
WEEKLY
INJECTIONS OF FX-322 DID NOT DEMONSTRATE IMPROVEMENTS IN ANY
HEARING MEASURES VERSUS PLACEBO
    * FREQUENCY THERAPEUTICS - OBSERVED THERE WAS UNEXPECTED
INCREASE
IN WR SCORES IN PLACEBO GROUP THAT DID NOT OCCUR IN PREVIOUS
FX-322 TRIALS
    * FREQUENCY THERAPEUTICS - UNABLE TO EVALUATE HEARING
IMPROVEMENTS
IN WR SCORES FOR FX-322 DOSING REGIMENS VERSUS PLACEBO
    * FREQUENCY THERAPEUTICS - FX-322 CONTINUES TO HAVE A
FAVORABLE
SAFETY AND TOLERABILITY PROFILE
    * FREQUENCY THERAPEUTICS - THERE WERE HIGHER RATE OF
EAR-RELATED
ADVERSE EVENTS NOTED IN PHASE 2A STUDY VERSUS PRIOR FX-322
SINGLE-DOSE STUDIES
    * FREQUENCY THERAPEUTICS - AES OCCURRED EARLY IN COURSE OF
TREATMENT AND WERE MILD AND TRANSIENT IN NATURE, NO PATIENTS
WITHDREW FROM PHASE 2A STUDY DUE TO SUCH AES

Source text (https://bit.ly/2Tfe3Yn)
Further company coverage:  FREQ.O 

 ((Reuters.Briefs@thomsonreuters.com;))